About OpGen (NASDAQ:OPGN)
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPGN
CUSIPN/A
Phone240-813-1260
Debt
Debt-to-Equity Ratio0.09%
Current Ratio0.73%
Quick Ratio0.62%
Price-To-Earnings
Trailing P/E Ratio-0.22
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.21 million
Price / Sales3.59
Cash FlowN/A
Price / CashN/A
Book Value$0.62 per share
Price / Book3.52
Profitability
EPS (Most Recent Fiscal Year)($9.78)
Net Income$-15,410,000.00
Net Margins-479.38%
Return on Equity-1,719.89%
Return on Assets-228.38%
Miscellaneous
Employees43
Outstanding Shares5,290,000
OpGen (NASDAQ:OPGN) Frequently Asked Questions
What is OpGen's stock symbol?
OpGen trades on the NASDAQ under the ticker symbol "OPGN."
When did OpGen's stock split? How did OpGen's stock split work?
OpGen shares reverse split on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.
How were OpGen's earnings last quarter?
OpGen (NASDAQ:OPGN) announced its quarterly earnings data on Thursday, March, 15th. The medical research company reported ($1.33) earnings per share for the quarter, beating analysts' consensus estimates of ($1.38) by $0.05. The medical research company earned $0.99 million during the quarter, compared to analysts' expectations of $0.81 million. OpGen had a negative return on equity of 1,719.89% and a negative net margin of 479.38%. View OpGen's Earnings History.
When is OpGen's next earnings date?
What price target have analysts set for OPGN?
2 brokers have issued 1-year price targets for OpGen's stock. Their forecasts range from $9.00 to $9.00. On average, they expect OpGen's stock price to reach $9.00 in the next year. View Analyst Ratings for OpGen.
Who are some of OpGen's key competitors?
Some companies that are related to OpGen include AmpliPhi Biosciences (APHB), EnteroMedics (RSLS), Cellectar Biosciences (CLRB), ESSA Pharma (EPIX), Bio-Path (BPTH), TrovaGene (TROV), Sonoma Pharmaceuticals (SNOA), Cormedix (CRMD), Xenetic Biosciences (XBIO), Cesca Therapeutics (KOOL), Cytori Therapeutics (CYTX), ValiRx (VAL), Cyclacel (CYCC), Fibrocell (FCSC), Ultima (N4P), Biocept (BIOC), Achieve Life Sciences (ACHV) and Prana Biotechnology (PRAN).
Who are OpGen's key executives?
OpGen's management team includes the folowing people:
- Mr. Evan Jones, Chairman & CEO (Age 61)
- Mr. Timothy C. Dec, CFO, Principal Accounting Officer & Corp. Sec. (Age 59)
- Mr. Vadim Sapiro, Chief Information Officer (Age 47)
- Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 59)
- Mr. Michael Farmer, Director of Marketing
When did OpGen IPO?
(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.
Has OpGen been receiving favorable news coverage?
News coverage about OPGN stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. OpGen earned a news impact score of 0.17 on Accern's scale. They also gave press coverage about the medical research company an impact score of 46.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are OpGen's major shareholders?
OpGen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include
SABBY MANAGEMENT, LLC
(5.17%) and
SABBY MANAGEMENT, LLC
(5.17%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.
How do I buy shares of OpGen?
Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OpGen's stock price today?
One share of OPGN stock can currently be purchased for approximately $2.18.
How big of a company is OpGen?
OpGen has a market capitalization of $10.95 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe.
How can I contact OpGen?
OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]opgen.com.
MarketBeat Community Rating for OpGen (OPGN)
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
OpGen (NASDAQ:OPGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for OpGen in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 312.84%. The high price target for OPGN is $9.00 and the low price target for OPGN is $9.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.00 | $9.00 | $25.00 | $25.00 |
| Price Target Upside: | 312.84% upside | 294.74% upside | 251.99% upside | 228.95% upside |
OpGen (NASDAQ:OPGN) Consensus Price Target History
OpGen (NASDAQ:OPGN) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
OpGen (NASDAQ:OPGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OpGen (NASDAQ OPGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 31.83%
OpGen (NASDAQ OPGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/18/2017 | Jven Capital, Llc | Chairman | Buy | 1,875,000 | $0.40 | $750,000.00 | |  |
| 7/18/2017 | Timothy C Dec | CFO | Buy | 65,000 | $0.40 | $26,000.00 | 118,966 | |
(Data available from 1/1/2013 forward)
OpGen (NASDAQ OPGN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | US STOCKS ON THE MOVE-Philip Morris, AmEx, Amazon, P&G, ChannelAdvisor
www.nasdaq.com - April 19 at 5:45 PM |
 | OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations
finance.yahoo.com - April 19 at 5:45 PM |
 | This Morning's Technical Outlook on Medical Research Stocks -- Invitae, IQVIA, Laboratory Corp., and OpGen
www.prnewswire.com - April 17 at 8:24 AM |
 | OpGen (OPGN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 17 at 4:11 AM |
| Comparing Genomic Health (GHDX) & OpGen (OPGN)
www.americanbankingnews.com - April 16 at 1:21 AM |
| HC Wainwright Analysts Give OpGen (OPGN) a $25.00 Price Target
www.americanbankingnews.com - April 11 at 11:52 PM |
| OpGen (OPGN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 9:52 AM |
| OpGen (OPGN) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 10 at 12:01 PM |
| OpGen (OPGN) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 5 at 9:36 PM |
| HC Wainwright Analysts Give OpGen (OPGN) a $9.00 Price Target
www.americanbankingnews.com - April 5 at 12:27 PM |
| Critical Survey: OpGen (OPGN) versus Magellan Health (MGLN)
www.americanbankingnews.com - March 29 at 3:34 PM |
| HC Wainwright Boosts OpGen (OPGN) Price Target to $9.00
www.americanbankingnews.com - March 25 at 8:16 AM |
| OpGen (OPGN) Given a $9.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 16 at 7:46 PM |
 | OpGen's (OPGN) CEO Evan Jones on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 6:33 PM |
| Edited Transcript of OPGN earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 6:33 PM |
 | OpGen Reports Fourth Quarter and Full Year 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:14 AM |
| OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
finance.yahoo.com - March 15 at 6:17 PM |
| Wired News – OpGen Announces Collaborator in Verification Study for Acuitas® Tests
finance.yahoo.com - March 15 at 8:11 AM |
| OpGen Inc (OPGN) Expected to Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - March 14 at 2:52 AM |
| OpGen (OPGN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:35 AM |
| OpGen (OPGN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:45 AM |
| OpGen Announces Collaborator in Verification Study for Acuitas® Test - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:18 AM |
| OpGen Announces Collaborator in Verification Study for Acuitas® Test
finance.yahoo.com - March 13 at 8:18 AM |
| OpGen Inc (OPGN) Expected to Post Earnings of -$1.50 Per Share
www.americanbankingnews.com - March 12 at 11:08 PM |
| OpGen (OPGN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 10 at 4:20 PM |
| Head to Head Review: OpGen (OPGN) & Codexis (CDXS)
www.americanbankingnews.com - March 8 at 5:11 PM |
| OpGen Announces Date of Fourth Quarter and Fiscal Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:12 AM |
| Has OpGen Inc (NASDAQ:OPGN) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 6 at 8:12 AM |
| OpGen to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 1 at 5:55 PM |
| $810,000.00 in Sales Expected for OpGen Inc (OPGN) This Quarter
www.americanbankingnews.com - February 25 at 1:44 AM |
| Zacks: Analysts Expect OpGen Inc (OPGN) Will Post Earnings of -$1.38 Per Share
www.americanbankingnews.com - February 23 at 11:12 PM |
| OpGen (OPGN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 16 at 6:46 AM |
| OpGen (OPGN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - February 15 at 6:26 AM |
 | BRIEF-OpGen Says Entered Agreement To Use Thermo Fisher's Real-Time PCR Technology In Co's New Acuitas Tests
www.reuters.com - February 13 at 9:22 AM |
| OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests
finance.yahoo.com - February 13 at 9:22 AM |
| OpGen Announces Closing of $12 Million Public Offering
finance.yahoo.com - February 7 at 8:58 AM |
| Brokerages Anticipate OpGen Inc (OPGN) to Post -$1.38 Earnings Per Share
www.americanbankingnews.com - February 6 at 11:22 PM |
| OpGen regains Nasdaq compliance but Wall Street woes continue
finance.yahoo.com - February 5 at 3:38 PM |
| OpGen Regains Compliance With Nasdaq Listing Requirements - GlobeNewswire (press release)
globenewswire.com - February 5 at 9:11 AM |
| OpGen Regains Compliance With Nasdaq Listing Requirements
finance.yahoo.com - February 5 at 9:11 AM |
| OpGen (OPGN) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - February 4 at 6:36 PM |
| OpGen Announces Pricing of $12 Million Upsized Public Offering - GlobeNewswire (press release)
globenewswire.com - February 4 at 8:58 AM |
 | OpGen (OPGN) Prices 3.7M Share Upsized Common Offering at $3.25/Sh
www.streetinsider.com - February 2 at 8:52 AM |
| OpGen Introduces New RUO Rapid Test for Infection Control and Surveillance Studies
finance.yahoo.com - February 1 at 9:16 AM |
| Zacks: OpGen Inc (OPGN) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 27 at 9:14 PM |
| OpGen (OPGN) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - January 25 at 6:58 PM |
| Is OpGen Inc’s (NASDAQ:OPGN) CEO Incentives Align With Yours?
finance.yahoo.com - January 25 at 9:05 AM |
| Zacks: Analysts Expect OpGen Inc (OPGN) Will Announce Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 23 at 1:48 PM |
| Brokerages Expect OpGen Inc (OPGN) to Post ($1.38) Earnings Per Share
www.americanbankingnews.com - January 20 at 9:42 AM |
| OpGen shareholders approve reverse stock split in bid to avoid delisting
finance.yahoo.com - January 18 at 11:12 AM |
OpGen (NASDAQ:OPGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OpGen (NASDAQ:OPGN) Income Statement, Balance Sheet and Cash Flow Statement
OpGen (NASDAQ OPGN) Stock Chart for Thursday, April, 19, 2018
Loading chart…
